Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475485 | 1.00 | CRBN (0.62) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20919946 | 0.99 | CRBN (0.61) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL26147866 | 0.99 | CRBN (0.61) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Hydrochloric Acid SCHEMBL31307049 | 0.96 | CRBN (0.62) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23705654 | 0.93 | CRBN (0.65) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29617032 | 0.93 | CRBN (0.65) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30432049 | 0.90 | CRBN (0.60) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20046344 | 0.90 | CRBN (0.60) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22276613 | 0.89 | CRBN (0.60) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23267590 | 0.89 | CRBN (0.60) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071552-B | Degradation of cyclin dependent kinase 4/6(CDK4/6) by conjugation of CDK4/6 inhibitors to E3 ligase ligands and methods of use | 达纳－法伯癌症研究所公司 | 2022-06-03 | — | — | CN | disclosed |